298 related articles for article (PubMed ID: 16288293)
1. Akt-regulated pathways in prostate cancer.
Majumder PK; Sellers WR
Oncogene; 2005 Nov; 24(50):7465-74. PubMed ID: 16288293
[TBL] [Abstract][Full Text] [Related]
2. Depletion of SAG/RBX2 E3 ubiquitin ligase suppresses prostate tumorigenesis via inactivation of the PI3K/AKT/mTOR axis.
Tan M; Xu J; Siddiqui J; Feng F; Sun Y
Mol Cancer; 2016 Dec; 15(1):81. PubMed ID: 27955654
[TBL] [Abstract][Full Text] [Related]
3. What controls PTEN and what it controls (in prostate cancer).
Ghosh PM
Asian J Androl; 2012 Jan; 14(1):130-1. PubMed ID: 21946231
[No Abstract] [Full Text] [Related]
4. [Role of PTEN protein in multidrug resistance of prostate cancer cells].
Sherbakova EA; Stromskaia TP; Rybalkina EIu; Kalita OV; Stavrovskaia AA
Mol Biol (Mosk); 2008; 42(3):487-93. PubMed ID: 18702307
[TBL] [Abstract][Full Text] [Related]
5. Role of mTOR signaling pathway proteins and proteins influencing mTOR pathway in resistance to radiotherapy in prostate cancer.
Benderli Cihan Y
J BUON; 2018; 23(6):1931-1932. PubMed ID: 30610829
[No Abstract] [Full Text] [Related]
6. AKT-mediated stabilization of histone methyltransferase WHSC1 promotes prostate cancer metastasis.
Li N; Xue W; Yuan H; Dong B; Ding Y; Liu Y; Jiang M; Kan S; Sun T; Ren J; Pan Q; Li X; Zhang P; Hu G; Wang Y; Wang X; Li Q; Qin J
J Clin Invest; 2017 Apr; 127(4):1284-1302. PubMed ID: 28319045
[TBL] [Abstract][Full Text] [Related]
7. HER2 Mediates PSMA/mGluR1-Driven Resistance to the DS-7423 Dual PI3K/mTOR Inhibitor in PTEN Wild-type Prostate Cancer Models.
Gómez V; Galazi M; Weitsman G; Monypenny J; Al-Salemee F; Barber PR; Ng K; Beatson R; Szokol B; Orfi L; Mullen G; Vanhaesebroeck B; Chowdhury S; Leung HY; Ng T
Mol Cancer Ther; 2022 Apr; 21(4):667-676. PubMed ID: 35086953
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic resistance resulting from mutations in Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR signaling pathways.
McCubrey JA; Steelman LS; Kempf CR; Chappell WH; Abrams SL; Stivala F; Malaponte G; Nicoletti F; Libra M; Bäsecke J; Maksimovic-Ivanic D; Mijatovic S; Montalto G; Cervello M; Cocco L; Martelli AM
J Cell Physiol; 2011 Nov; 226(11):2762-81. PubMed ID: 21302297
[TBL] [Abstract][Full Text] [Related]
9. Analysis of complex protein kinase B signalling pathways in human prostate cancer samples.
Jendrossek V; Henkel M; Hennenlotter J; Vogel U; Ganswindt U; Müller I; Handrick R; Anastasiadis AG; Kuczyk M; Stenzl A; Belka C
BJU Int; 2008 Aug; 102(3):371-82. PubMed ID: 18476967
[TBL] [Abstract][Full Text] [Related]
10. Deregulated PTEN/PI3K/AKT/mTOR signaling in prostate cancer: Still a potential druggable target?
Braglia L; Zavatti M; Vinceti M; Martelli AM; Marmiroli S
Biochim Biophys Acta Mol Cell Res; 2020 Sep; 1867(9):118731. PubMed ID: 32360668
[TBL] [Abstract][Full Text] [Related]
11. PTEN deficiency is fully penetrant for prostate adenocarcinoma in C57BL/6 mice via mTOR-dependent growth.
Blando J; Portis M; Benavides F; Alexander A; Mills G; Dave B; Conti CJ; Kim J; Walker CL
Am J Pathol; 2009 May; 174(5):1869-79. PubMed ID: 19395652
[TBL] [Abstract][Full Text] [Related]
12. Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics.
Zhong H; Chiles K; Feldser D; Laughner E; Hanrahan C; Georgescu MM; Simons JW; Semenza GL
Cancer Res; 2000 Mar; 60(6):1541-5. PubMed ID: 10749120
[TBL] [Abstract][Full Text] [Related]
13. Signal transduction pathways in androgen-dependent and -independent prostate cancer cell proliferation.
Ghosh PM; Malik SN; Bedolla RG; Wang Y; Mikhailova M; Prihoda TJ; Troyer DA; Kreisberg JI
Endocr Relat Cancer; 2005 Mar; 12(1):119-34. PubMed ID: 15788644
[TBL] [Abstract][Full Text] [Related]
14. Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance.
McCubrey JA; Steelman LS; Abrams SL; Lee JT; Chang F; Bertrand FE; Navolanic PM; Terrian DM; Franklin RA; D'Assoro AB; Salisbury JL; Mazzarino MC; Stivala F; Libra M
Adv Enzyme Regul; 2006; 46():249-79. PubMed ID: 16854453
[TBL] [Abstract][Full Text] [Related]
15. PI3K-AKT-mTOR pathway is dominant over androgen receptor signaling in prostate cancer cells.
Kaarbø M; Mikkelsen OL; Malerød L; Qu S; Lobert VH; Akgul G; Halvorsen T; Maelandsmo GM; Saatcioglu F
Cell Oncol; 2010; 32(1-2):11-27. PubMed ID: 20203370
[TBL] [Abstract][Full Text] [Related]
16. Clinical significance of genetic variations in the PI3K/PTEN/AKT/mTOR pathway in Korean patients with colorectal cancer.
Kim JG; Chae YS; Sohn SK; Kang BW; Moon JH; Lee SJ; Jeon SW; Park JS; Park JY; Choi GS
Oncology; 2010; 79(3-4):278-82. PubMed ID: 21412012
[TBL] [Abstract][Full Text] [Related]
17. Prostate cancer heterogeneity: Discovering novel molecular targets for therapy.
Ciccarese C; Massari F; Iacovelli R; Fiorentino M; Montironi R; Di Nunno V; Giunchi F; Brunelli M; Tortora G
Cancer Treat Rev; 2017 Mar; 54():68-73. PubMed ID: 28231559
[TBL] [Abstract][Full Text] [Related]
18. [PI3K-AKT-mTOR pathway inhibitors].
Cortot A; Armand JP; Soria JC
Bull Cancer; 2006 Jan; 93(1):19-26. PubMed ID: 16455502
[TBL] [Abstract][Full Text] [Related]
19. [Dermatological implications of the PI3K pathway].
Dereure O
Ann Dermatol Venereol; 2015 Oct; 142(10):622-3. PubMed ID: 26001484
[No Abstract] [Full Text] [Related]
20. Oncogenic and Therapeutic Targeting of PTEN Loss in Bone Malignancies.
Xi Y; Chen Y
J Cell Biochem; 2015 Sep; 116(9):1837-47. PubMed ID: 25773992
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
